drugset
drugset / Trial / NCT06306872

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

NCT06306872 ↗

Phase 1 Completed 40 enrolled Abbisko Therapeutics Co, Ltd
RandomizedCrossoverOpen-labelOther

Summary

The main objective of which is to evaluate the relative bioavailability and PK characteristics of new and old ABSK-011 capsules in a single oral dose

Timeline

Start
2024-02-23
Primary completion
2025-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ABSK-011 Unknown 200 mg Oral
Subject ABSK-011 Unknown 220 mg Oral

Indications

No indication recorded.